

PRODUCT INFORMATION

| Clone ID | DMC440 |
|---------------------------------|--|
| Target | UPA |
| Synonyms | ATF; BDPLT5; QPD; u-PA; UPA; URK |
| Host Species | Rabbit |
| Description | Biotinylated Anti-UPA antibody(DMC440); lgG1 Chimeric mAb |
| Delivery | 2-3 weeks |
| Uniprot ID | P00749 |
| lgG type | Rabbit/Human Fc chimeric lgG1 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Applications | Flow Cyt |
| Recommended Dilutions | Flow Cyt 1:100 |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. Store at -20°C to -80°C for 12 months in |
| Storage & Shipping | lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants; at least one of which encodes an isoform that is proteolytically processed. |
| Usage | Research use only |
| Conjugate | Biotinylated |
| DIMA Disclaimer | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

Email: info@dimabio.com Website: www.dimabio.com

